These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 1709846)
1. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Illingworth DR Drugs; 1991 Feb; 41(2):151-60. PubMed ID: 1709846 [No Abstract] [Full Text] [Related]
2. Pravastatin and simvastatin for hypercholesterolemia. Med Lett Drugs Ther; 1991 Mar; 33(839):18-20. PubMed ID: 1899899 [No Abstract] [Full Text] [Related]
3. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias. Aronson JK; Ng LL Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916 [No Abstract] [Full Text] [Related]
4. Comparison of different HMG-CoA reductase inhibitors. Ditschuneit HH; Kuhn K; Ditschuneit H Eur J Clin Pharmacol; 1991; 40 Suppl 1():S27-32. PubMed ID: 1904357 [TBL] [Abstract][Full Text] [Related]
5. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Maher VM; Thompson GR Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
8. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069 [TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]. Carmena R Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284 [No Abstract] [Full Text] [Related]
10. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS; Fong NT Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596 [TBL] [Abstract][Full Text] [Related]
11. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Tobert JA Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437 [TBL] [Abstract][Full Text] [Related]
17. Pravastatin--ocular side effects after a two year follow-up? Behrens-Baumann W; Thiery J; Fieseler HG; Seidel D Lens Eye Toxic Res; 1990; 7(3-4):311-8. PubMed ID: 2129219 [TBL] [Abstract][Full Text] [Related]
18. Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations. Med Lett Drugs Ther; 1992 Jun; 34(872):57-8. PubMed ID: 1593973 [No Abstract] [Full Text] [Related]
19. Peripheral neuropathy and lipid-lowering therapy. Ziajka PE; Wehmeier T South Med J; 1998 Jul; 91(7):667-8. PubMed ID: 9671841 [TBL] [Abstract][Full Text] [Related]